Cytisinicline

Name: Cytisinicline in Smoking cessation: Product comparison
Published: 2026-09-14T15:39:06-04:00

Smoking cessation

Manufacturer: Achieve Life Sciences
Regulatory submission: NDA resubmission planned for the fourth quarter of 2026
Launch: Anticipated after potential approval in the first half of 2027
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information

Product comparison

2 evidence topics · 6 sources

Cochrane: cytisine versus placebo

“moderate-certainty evidence (limited by heterogeneity)” (opens the source at this quote in a new tab)
“RR 1.30, 95% confidence interval (CI) 1.15 to 1.47” (opens the source at this quote in a new tab)
“4 studies, 4623 participants” (opens the source at this quote in a new tab)

Systematic review and meta-analyses

Comparison	Quoted relative effect	Participants	Certainty
Cytisine versus placebo or no medication	“RR 2.65 (1.50 to 4.67)”	“5194”	“Moderate”
Cytisine versus nicotine-replacement therapy	“RR 1.36 (1.06–1.73)”	“1511”	“Moderate”
Cytisine versus varenicline	“RR 0.96 (0.63–1.45)”	“2508”	“Low”
Longer versus shorter treatment duration	“RR 1.29 (1.02–1.63)”	“1009”	“Moderate”